Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06410976 · ClinicalTrials.gov registry record
Prospective Clinical Assessment Study in Children With Hypochondroplasia
A clinical trial of Hypochondroplasia, sponsored by QED Therapeutics, a BridgeBio company.
- Recruiting
- Registry status
- 150
- Enrollment target
- 20
- Study locations
NCT06410976 is a study of Hypochondroplasia that is actively recruiting participants, run by QED Therapeutics, a BridgeBio company. The registered enrollment target is 150 participants, roughly in line with the 158-participant average among 4 other Hypochondroplasia trials with a reported enrollment target. The trial reports 20 study locations across 12 states.
The verdict
NCT06410976, a study of Hypochondroplasia, is actively recruiting participants, sponsored by QED Therapeutics, a BridgeBio company.
- RECRUITING
- Registry status
- 150 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a long-term, multicenter, non-interventional study of children ages 2.5 to \<17 years with hypochondroplasia (HCH).
Conditions Studied
Study Locations (20)
Other
- Hôpital Femme Mère Enfant HCL - Bron
- Hôpital Necker-Enfants Malades - Paris
- Centre Hospitalier Universitaire (CHU) de Toulouse - Hôpital des Enfants - Toulouse
- Haukeland University Hospital - Bergen
- Paediatric Clinical Research Unit at Oslo University Hospital - Oslo
- Hospital Pediátrico de Coimbra - Coimbra
- KK Women's and Children's Hospital - Singapore
- Hospital Vithas San Jose - Vitoria-Gasteiz
Ontario
- London Health Sciences Centre - Children's Hospital of Western Ontario - London
- Children's Hospital of Eastern Ontario Research Institute - Ottawa
California
- UCSF Benioff Children's Hospital - Oakland
Colorado
- Childrens Hospital Colorado - Aurora
District of Columbia
- Children's National Hospital - Washington D.C.
Maryland
- Johns Hopkins School of Medicine - Baltimore
Missouri
- University of Missouri - Columbia
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2024-06-05 |
| Est. Completion | 2026-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06410976
The ClinicalTrials.gov registry entry for NCT06410976 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 158-participant average among 4 other Hypochondroplasia trials with a reported enrollment target. The listed sponsor is QED Therapeutics, a BridgeBio company, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypochondroplasia appearing as the primary indexed condition, and to 0 interventions.
NCT06410976 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, Ontario, California.
Frequently Asked Questions
What is clinical trial NCT06410976 about?
NCT06410976 is a clinical study titled "Prospective Clinical Assessment Study in Children With Hypochondroplasia". This is a long-term, multicenter, non-interventional study of children ages 2.5 to \<17 years with hypochondroplasia (HCH).
What is the current status of trial NCT06410976?
This trial is currently recruiting. The enrollment target is 150 participants. The study started on 2024-06-05. Estimated completion is 2026-10.
What conditions does trial NCT06410976 study?
This clinical trial studies the following conditions: Hypochondroplasia.
Who is sponsoring clinical trial NCT06410976?
This trial is sponsored by QED Therapeutics, a BridgeBio company, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06410976 being conducted?
This trial has 20 study locations across California, Colorado, District of Columbia, Maryland, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypochondroplasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months
RECRUITING · Phase 2
-
A Multicenter Multinational Observational Study of Children With Hypochondroplasia
RECRUITING
-
Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia
ACTIVE NOT RECRUITING · Phase 3
-
C-Type Natriuretic Peptide and Achondroplasia
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.